Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Polyphor AG    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/13/2019 08/14/2019 08/15/2019 08/16/2019 08/19/2019 Date
4.48(c) 4.64(c) 4.4(c) 4.465(c) 4.4 Last
34 993 33 875 84 898 62 726 49 655 Volume
-1.32% +3.57% -5.17% +1.48% -1.46% Change
More quotes
Financials (CHF)
Sales 2019 0,86 M
EBIT 2019 -55,9 M
Net income 2019 -55,6 M
Finance 2019 80,7 M
Yield 2019 -
Sales 2020 9,89 M
EBIT 2020 -47,7 M
Net income 2020 -51,9 M
Finance 2020 35,7 M
Yield 2020 -
P/E ratio 2019 -0,89x
P/E ratio 2020 -0,95x
EV / Sales2019 -36,6x
EV / Sales2020 1,38x
Capitalization 49,3 M
More Financials
Company
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas... 
Sector
Pharmaceuticals
Calendar
09/05Earnings Release
More about the company
Surperformance© ratings of Polyphor AG
Trading Rating : Investor Rating :
More Ratings
Latest news on POLYPHOR AG
07/18POLYPHOR : closes the Phase III PRISM studies of murepavadin intravenous formula..
AQ
07/17POLYPHOR : closes the Phase III PRISM studies of murepavadin intravenous formula..
EQ
06/27POLYPHOR : appoints Frank Weber as new Chief Medical and Development Officer
EQ
06/20POLYPHOR : to present its antibiotic programs at the American Society of Microbi..
EQ
06/19POLYPHOR : announces enrollment of first patient in FORTRESS Phase III clinical ..
EQ
06/07POLYPHOR : presents new in-vivo efficacy and tolerability data for a potential i..
EQ
05/29POLYPHOR : and the University of Zurich receive an award from Innosuisse to acce..
EQ
05/17POLYPHOR : announces presentation of new survival data on balixafortide at the A..
EQ
05/09POLYPHOR : temporarily halts enrollment in the Phase III studies of murepavadin ..
EQ
04/17POLYPHOR : announces enrollment of first patient in PRISM-UDR - the second, FDA ..
AQ
More news
Sector news : Biopharmaceuticals
10:27aALLERGAN : Form 8.3 - Allergan Plc
DJ
03:20aNOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
02:48aNOVARTIS : CEO Under Fire Over Drug Data
DJ
08/18NOVARTIS : executive sold shares before drug data manipulation made public
RE
08/18NOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
More sector news : Biopharmaceuticals
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 12,70  CHF
Last Close Price 4,47  CHF
Spread / Highest target 258%
Spread / Average Target 184%
Spread / Lowest Target 111%
EPS Revisions
Managers
NameTitle
Giacomo di Nepi Chief Executive Officer
Argeris N. Karabelas Chairman
Kalina Scott Chief Financial Officer
Daniel Obrecht Chief Scientific Officer
Frank Weber Director, Chief Medical & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
POLYPHOR AG-74.97%50
CSL LIMITED22.81%69 599
BIOGEN INC.-23.01%41 986
ALEXION PHARMACEUTICALS13.86%24 450
GRIFOLS25.41%19 155
SAMSUNG BIOLOGICS CO LTD--.--%15 813